J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.
Stock News Wall Street jumps on rate-cut hopes: Alphabet (GOOGL) and Tesla (TSLA) led a tech rebound as odds of a December Fed cut climbed, lifting the Nasdaq 2
Advisors Asset Management Inc. trimmed its position in shares of Johnson and Johnson (NYSE: JNJ) by 1.5% during the second quarter, according to the company in its most recent Form 13F filing with the
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by
Aviso Financial Inc. reduced its stake in Johnson and Johnson (NYSE: JNJ) by 8.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Comm
Armor Investment Advisors LLC reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 12.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange
Associated Banc Corp trimmed its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and
Johnson and Johnson (NYSE: JNJ - Get Free Report) saw unusually large options trading activity on Monday. Stock investors bought 201,479 call options on the stock. This represents an increase of 468%
Bahl and Gaynor Inc. raised its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 15.5% during the second quarter, according to the company in its most recent disclosure with the Securities and
AlphaCore Capital LLC boosted its stake in Johnson and Johnson (NYSE: JNJ) by 27.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund
Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares t
J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Aspen Investment Management Inc decreased its stake in shares of Johnson and Johnson (NYSE: JNJ) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exch
ARS Investment Partners LLC boosted its holdings in Johnson and Johnson (NYSE: JNJ) by 2.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exc
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE